Early ART start to prevent later cognitive decline

Organisation: Position: Deadline Date: Location:

Individuals who start HIV treatment very soon after contracting the virus may be at lesser risk of later developing cognitive decline than other HIV-positive individuals. Researchers conducted a cross-sectional observational study of 26 males living with HIV who started antiretroviral (ARV) treatment during primary infection, had an undetectable viral load, and did not have certain neuro-psychiatric conditions.

HIV-positive people, on average, have a higher risk of cognitive decline than the general population. The mean age of the men in this study was 43. They had a median CD4 count of 828, a median lowest-ever CD4 count of 359, and had been on ARVs for a median 5.7 years. Only one of the participants, or 4% of the total, had cognitive impairment.

The researchers concluded that early HIV treatment may help protect against HIV-associated neurocognitive disorders.

Abstract
Objective: To determine the prevalence of HIV-associated neurocognitive disorders (HAND) in HIV-infected participants who initiated combination antiretroviral therapy (cART) during primary infection.
Design: Cross-sectional observational study.
Methods: HIV-infected men without neuropsychiatric confounds who had initiated cART during primary infection were administered a neuropsychological battery as well as questionnaires evaluating depression and quality of life. Eligibility was determined by a medical examination with history and review of records.
Results: Twenty-six primarily non-Hispanic white (73%), male (100%) participants were enrolled and underwent neurocognitive assessment. Mean age was 43 (28–71) years, with a median of 17 years of education (13–24). Median current and nadir CD4+ T-cell counts were 828 (506–1411) and 359 (150–621) cells/μl. All participants had plasma HIV-1 RNA less than 50 copies/ml. Median duration of cART prior to enrolment was 5.7 years (2.2–9.9). Median global deficit score was 0.17 (0.00–0.60). Only one (4%) participant was impaired.
Conclusion: Rates of HAND in this cohort of HIV-infected men without comorbid conditions who initiated early cART are low. Our findings suggest a possible neuroprotective benefit of early cART and an important contribution of comorbidities to observed HAND prevalence.

Aidsmeds material
AIDS abstract


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.